Bluejay Diagnostics, Inc. (NASDAQ:BJDX)
| Market Cap | 835.95K-88.9% |
| Revenue (ttm) | 0 |
| Net Income | -7.27M-8.0% |
| EPS | -11.80+97.6% |
| Shares Out | 1.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,840 |
| Open | 0.80 |
| Previous Close | 0.81 |
| Day's Range | 0.79 - 0.83 |
| 52-Week Range | 0.76 - 16.68 |
| Beta | 0.89 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About BJDX
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BJDX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BJDX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BJDX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BJDX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New BJDX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BJDX from public contracts
Source: USAspending.gov
BJDX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BJDX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score